Using decitabine alone or with other drugs to maintain remission in acute myeloid leukemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase Ib trial evaluates the safety and potential benefits of decitabine, both alone and in combination with venetoclax, gilteritinib, enasidenib, or ivosidenib, for patients with acute myeloid leukemia (AML) who are in remission. The study aims to determine how well these treatments can maintain remission and improve survival outcomes. Patients will be assigned to different treatment arms based on their previous therapy, and the trial will assess various survival metrics and the dynamics of minimal residual disease. The goal is to find effective maintenance therapies that can help control the disease after initial treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients aged \>= 18 years AML who have achieved their FIRST complete response (CR) or complete response with incomplete bone marrow recovery (CRi) and are not immediately candidates for allogeneic stem cell transplant
* Patients who have received intensive therapy (defined as receiving standard or higher dose cytarabine-based therapy) to achieve remission (CR/CRi) should have received remission induction therapy and at least 1 consolidation cycle. These patients are eligible as long as they are not greater than 2 months from their last consolidation therapy and will be designated as COHORT 1 (intensive induction cohort)
* Patients who have received lower intensity therapy (defined as receiving low-dose cytarabine \[LDAC\] or hypomethylating agent \[HMA\]-based therapy) to achieve remission should have received at least 2 cycles of lower intensity therapy between the time they have achieved CR/CRi and enrollment on this protocol. They will be designated as COHORT 2 (lower intensity induction cohort)
* For either subgroup (lower or higher intensity), patients who have measurable residual disease may be enrolled on their respective cohort at any time without maximum 'time from consolidation' requirement
* Eastern Cooperative Oncology Group (ECOG) performance status of \< or = 3
* Serum total bilirubin \< or = to 1.5 x the upper limit of normal (ULN)
* Serum creatinine \< or = to 2.5 x ULN
* Absolute neutrophil count (ANC) \> 0.5 x k/uL
* Platelet count \> or = 50 x k/uL
* For females of childbearing age, they may participate if they:

  * Have a negative serum or urine pregnancy test within 10 to 14 days of enrolling
  * Agree to either abstinence or 2 effective contraceptive methods (such as barrier methods or hormonal contraception) throughout the treatment period and up to 30 days after discontinuing treatment
* For male patients with a female partner of childbearing age, they may participate if they agree to either abstinence or 2 effective contraceptive methods throughout the treatment period and up to 30 days after discontinuing treatment
* Ability to understand and sign informed consent

Exclusion Criteria:

* Diagnosis of acute promyelocytic leukemia (APL), AML - M3 by French-American-British (FAB) classification based on morphology, immunophenotype, molecular, or cytogenetics studies
* Diagnosis of AML associated t(15;17) or APL variant. Patients with t(9;22) are also ineligible unless they are unable or unwilling to receive therapy with a tyrosine kinase inhibitor
* Uncontrolled intercurrent illness including, but not limited to active uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
* Patients with active CNS (central nervous system) disease
* Patients with documented hypersensitivity to any components of the study program
* Females who are pregnant or lactating or intending to become pregnant during the study
* Patients with history of extramedullary AML, except for CNS involvement that is currently controlled, will not be eligible for enrollment
* Patient should be removed from current trial if they wish to participate and get treatment on another trial

Where it's running

• M D Anderson Cancer Center
  Houston, Texas, United States Recruiting

Study contacts

• Principal investigator: Tapan M Kadia, MD — M.D. Anderson Cancer Center
• Study coordinator: Tapan M. Kadia, MD
• Email: tkadia@mdanderson.org
• Phone: 713-792-7305

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Gilteritinib with Venetoclax and Azacitidine, then High‑Dose Cytarabine and Gilteritinib Maintenance for Newly Diagnosed FLT3‑ITD AML

  This approach tests whether combining gilteritinib with venetoclax and azacitidine for induction, followed by DeepScan‑guided high‑dose cytarabine consolidation and gilteritinib maintenance, can produce deep remissions and allow fit adults with newly diagnosed FLT3‑ITD AML to avoid transplant.

  Recruiting Phase 2 First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang · NCT07259707

• Combination treatment for FLT3-mutated acute myeloid leukemia and high-risk myelodysplastic syndrome

  This study is testing a new combination of three drugs to see if it can help people with FLT3-mutated acute myeloid leukemia or high-risk myelodysplastic syndrome feel better and live longer.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT05010122

• Comparing chemotherapy options for newly diagnosed acute myeloid leukemia

  This study is testing whether a new combination of treatments is better than standard chemotherapy for children and young adults with newly diagnosed acute myeloid leukemia.

  Recruiting at 188 sites Phase 3 Children's Oncology Group · Birmingham, Alabama and 205 other locations · NCT04293562

• Tailored exercise program to improve quality of life for adults with hematologic cancers

  This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.

  Recruiting Gruppo Italiano Malattie EMatologiche dell'Adulto · Roma, Rm and 2 other locations · NCT07912684

• Characterization of CD180 Protein Expression in Myeloid Blood C cancers

  This study tests how CD180 is presented on myeloid cancer cells and normal stem cells using existing patient samples from AML cases to see if it could help with diagnosis or monitoring.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07895901

• Personalized AML: Find biomarkers to predict response to venetoclax

  This study tests whether single-cell analyses can help group AML patients by biology and find biomarkers that predict who will respond to venetoclax.

  Recruiting Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Milan · NCT07874100

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.